X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PIRAMAL ENTERPRISES - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PIRAMAL ENTERPRISES SANOFI INDIA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 39.9 10.4 383.1% View Chart
P/BV x 8.6 1.8 479.8% View Chart
Dividend Yield % 1.0 0.9 115.3%  

Financials

 SANOFI INDIA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
PIRAMAL ENTERPRISES
Mar-18
SANOFI INDIA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs4,5603,083 147.9%   
Low Rs4,4001,902 231.3%   
Sales per share (Unadj.) Rs1,028.5589.7 174.4%  
Earnings per share (Unadj.) Rs129.0284.0 45.4%  
Cash flow per share (Unadj.) Rs186.0310.5 59.9%  
Dividends per share (Unadj.) Rs68.0025.00 272.0%  
Dividend yield (eoy) %1.51.0 151.3%  
Book value per share (Unadj.) Rs753.61,467.0 51.4%  
Shares outstanding (eoy) m23.03180.27 12.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.44.2 103.1%   
Avg P/E ratio x34.78.8 395.9%  
P/CF ratio (eoy) x24.18.0 300.1%  
Price / Book Value ratio x5.91.7 349.9%  
Dividend payout %52.78.8 599.1%   
Avg Mkt Cap Rs m103,174449,332 23.0%   
No. of employees `0003.66.8 52.9%   
Total wages/salary Rs m3,59219,881 18.1%   
Avg. sales/employee Rs Th6,537.715,535.6 42.1%   
Avg. wages/employee Rs Th991.42,905.4 34.1%   
Avg. net profit/employee Rs Th819.87,482.5 11.0%   
INCOME DATA
Net Sales Rs m23,686106,310 22.3%  
Other income Rs m7082,595 27.3%   
Total revenues Rs m24,394108,906 22.4%   
Gross profit Rs m5,28151,599 10.2%  
Depreciation Rs m1,3134,773 27.5%   
Interest Rs m1529,783 0.1%   
Profit before tax Rs m4,66119,638 23.7%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691-28,764 -5.9%   
Profit after tax Rs m2,97051,203 5.8%  
Gross profit margin %22.348.5 45.9%  
Effective tax rate %36.3-146.5 -24.8%   
Net profit margin %12.548.2 26.0%  
BALANCE SHEET DATA
Current assets Rs m15,673118,154 13.3%   
Current liabilities Rs m6,678462,260 1.4%   
Net working cap to sales %38.0-323.7 -11.7%  
Current ratio x2.30.3 918.2%  
Inventory Days Days7627 285.9%  
Debtors Days Days2247 47.9%  
Net fixed assets Rs m8,098113,727 7.1%   
Share capital Rs m230361 63.9%   
"Free" reserves Rs m17,088264,093 6.5%   
Net worth Rs m17,356264,454 6.6%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m25,400726,834 3.5%  
Interest coverage x311.71.7 18,786.4%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.90.1 637.6%   
Return on assets %11.811.1 105.5%  
Return on equity %17.119.4 88.4%  
Return on capital %26.910.3 261.4%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14515,110 47.3%   
Fx outflow Rs m6,8464,298 159.3%   
Net fx Rs m29910,813 2.8%   
CASH FLOW
From Operations Rs m3,226-159,666 -2.0%  
From Investments Rs m-1,555-17,677 8.8%  
From Financial Activity Rs m-1,818186,503 -1.0%  
Net Cashflow Rs m-1479,364 -1.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 4.0 360.0%  
FIIs % 14.6 26.6 54.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   15,184 93,274 16.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   MERCK LTD  STERLING BIOTECH  NATCO PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - WOCKHARDT LTD. COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS